Regulatory Coherence Sample Clauses

Regulatory Coherence. ‌ The focus of this chapter is on encouraging the development of domestic systems for assuring that regulation is designed to best achieve the Party’s public policy objectives, and that trade and investment liberalisation is taken into account when considering new regulation. It does this through creating obligations on all the CPTPP Parties to establish regulatory quality management systems of the type already maintained by some Parties, including New Zealand. It is intended to reflect a forward looking view of how best to reduce future barriers to trade and investment, by targeting behind the border barriers to trade. The chapter does not alter the sovereign right of the Parties to identify their regulatory priorities and to take regulatory action at the levels they consider appropriate. Regulatory quality management systems involve the use of good regulatory practice by Parties in planning, designing, issuing, implementing, and reviewing regulatory measures. New Zealand is largely already in compliance with the provisions in this Chapter, having a well-developed regulatory quality management system. The obligations generally attach to ‘covered regulatory measures’. Each Party would be able to determine the scope of covered regulatory measures. The scope of New Zealand's covered regulatory measures has not yet been determined, but given the focus of the CPTPP on trade and investment, it would likely be narrower in application than some of our existing regulatory management tools.
Sample 1Sample 2
AutoNDA by SimpleDocs
Regulatory Coherence. ‌ The focus of this chapter is on encouraging the development of domestic systems for assuring that regulation is designed to best achieve the Party’s public policy objectives, and that trade and investment liberalisation is taken into account when considering new regulation. It does this through creating obligations on all the CPTPP Parties to establish regulatory quality management systems of the type already maintained by some Parties, including New Zealand. It is intended to reflect a forward looking view of how best to reduce future barriers to trade and investment, by targeting behind the border barriers to trade. The chapter does not alter the sovereign right of the Parties to identify their regulatory priorities and to take regulatory action at the levels they consider appropriate. Regulatory quality management systems involve the use of good regulatory practice by Parties in planning, designing, issuing, implementing, and reviewing regulatory measures. New Zealand is largely already in compliance with the provisions in this Chapter, having a well-developed regulatory quality management system. The obligations generally attach to ‘covered regulatory measures’. Each Party would be able to determine the scope of covered regulatory measures. The scope of New Zealand's covered regulatory measures has not yet been determined, but given the focus of the CPTPP on trade and investment, it would likely be narrower in application than some of our existing regulatory management tools. Advantages to entering CPTPP, Regulatory Coherence Greater transparency of rulemaking in CPTPP Parties would benefit New Zealand businesses trading with or investing in these countries by providing greater certainty about the regulatory environment in which they are operating. It is difficult to estimate the size of the benefits transparency in rule making brings, but research40 indicates that transparency lowers the barriers to enter a market, benefitting businesses wanting to trade with or invest in countries and resulting in benefits to both the exporting and importing economies. The research indicated that if other APEC economies improved the transparency of their trade-related regulation, New Zealand exports could increase by approximately five percent (based on an analysis in 2009).41 It should be noted, however, that trade- facilitating regulatory improvements in other CPTPP countries would for the most part benefit CPTPP members and non-members alike. This benefit of the...
Sample 1

Related to Regulatory Coherence

  • Regulatory Compliance a. Monitor compliance with the 1940 Act requirements, including:

  • Clinical 2.1 Provides comprehensive evidence based nursing care to patients including assessment, intervention and evaluation.

  • REGULATORY FILINGS AND CAISO TARIFF COMPLIANCE 3.1 Filing

  • Regulatory Filing In the event that this Interconnection Construction Service Agreement contains any terms that deviate materially from the form included in Attachment P or from the standard terms and conditions in this Appendix 2, the Transmission Provider shall file the executed Interconnection Construction Service Agreement on behalf of itself and the Interconnected Transmission Owner with FERC as a service schedule under the Tariff. Interconnection Customer may request that any information so provided be subject to the confidentiality provisions of Section 17 of this Appendix

  • How to File an Appeal of a Prescription Drug Denial For denials of a prescription drug claim based on our determination that the service was not medically necessary or appropriate, or that the service was experimental or investigational, you may request an appeal without first submitting a request for reconsideration. You or your physician may file a written or verbal prescription drug appeal with our pharmacy benefits manager (PBM). The prescription drug appeal must be submitted to us within one hundred and eighty (180) calendar days of the initial determination letter. You will receive written notification of our determination within thirty (30) calendar days from the receipt of your appeal. How to File an Expedited Appeal Your appeal may require immediate action if a delay in treatment could seriously jeopardize your health or your ability to regain maximum function, or would cause you severe pain. To request an expedited appeal of a denial related to services that have not yet been rendered (a preauthorization review) or for on-going services (a concurrent review), you or your healthcare provider should call: • our Grievance and Appeals Unit; or • our pharmacy benefits manager for a prescription drug appeal. Please see Section 9 for contact information. You will be notified of our decision no later than seventy-two (72) hours after our receipt of the request. You may not request an expedited review of covered healthcare services already received.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • COVID-19 Protocols Contractor will abide by all applicable COVID-19 protocols set forth in the District’s Reopening and COVID-19 Mitigation Plan and the safety guidelines for COVID-19 prevention established by the California Department of Public Health and the Ventura County Department of Public Health.

  • Information Technology Accessibility Standards Any information technology related products or services purchased, used or maintained through this Grant must be compatible with the principles and goals contained in the Electronic and Information Technology Accessibility Standards adopted by the Architectural and Transportation Barriers Compliance Board under Section 508 of the federal Rehabilitation Act of 1973 (29 U.S.C. §794d), as amended. The federal Electronic and Information Technology Accessibility Standards can be found at: xxxx://xxx.xxxxxx-xxxxx.xxx/508.htm.

  • Study An application for leave of absence for professional study must be supported by a written statement indicating what study or research is to be undertaken, or, if applicable, what subjects are to be studied and at what institutions.

  • Regulatory Authority If any regulatory authority having jurisdiction (or any successor boards or agencies), a court of competent jurisdiction or other Governmental Authority with the appropriate jurisdiction (collectively, the ''Regulatory Body'') issues a rule, regulation, law or order that has the effect of cancelling, changing or superseding any term or provision of this Agreement (the ''Regulatory Requirement''), then this Agreement will be deemed modified to the extent necessary to comply with the Regulatory Requirement. Notwithstanding the foregoing, if a Regulatory Body materially modifies the terms and conditions of this Agreement and such modification(s) materially affect the benefits flowing to one or both of the Parties, as determined by either of the Parties within twenty (20) business days of the receipt of the Agreement as materially modified, the Parties agree to attempt in good faith to negotiate an amendment or amendments to this Agreement or take other appropriate action(s) so as to put each Party in effectively the same position in which the Parties would have been had such modification not been made. In the event that, within sixty (60) days or some other time period mutually agreed upon by the Parties after such modification has been made, the Parties are unable to reach agreement as to what, if any, amendments are necessary and fail to take other appropriate action to put each Party in effectively the same position in which the Parties would have been had such modification not been made, then either Party shall have the right to unilaterally terminate this Agreement forthwith.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!